High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
about
Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapyMaraviroc: a review of its use in HIV infection and beyondDevelopment of Human Membrane Transporters: Drug Disposition and PharmacogeneticsDevelopment of biomarkers to optimize pediatric patient management: what makes children different?OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesPediatric Statin Administration: Navigating a Frontier with Limited DataAssociation between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysisCharacterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical functionIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Prediction of hepatic clearance in human from in vitro data for successful drug development.Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participantsSynergistic interaction between genetics and disease on pravastatin dispositionApplication of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.Frequencies of two functionally significant SNPs and their haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in six ethnic groups of Pakistani population.The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substratesMechanisms and assessment of statin-related muscular adverse effects.Impact of OATP transporters on pharmacokinetics.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy[Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin responseA 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate dispositionSimvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideCommon nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studySLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patientsInhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.Statin response and pharmacokinetics variants.Clinical implications of pharmacogenomics of statin treatment.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
P2860
Q24676890-CAC571F0-BD5B-4A8F-BA9D-B96C2661ED01Q26778504-35DA91DC-BA2A-4576-8EEC-B4D09D09B25BQ26786582-03566869-00FE-4120-AF7D-9013FF9A9D9AQ26822946-B5F3C55C-7600-4EBC-8C65-EDA1E46735C2Q27001267-B121E67B-BA8F-4740-9FF9-E8553F1B34B8Q28068014-A67780E6-2072-4FD5-B9EE-9ACC67FF831CQ28070052-05731DFF-6DB5-43B6-9D4A-D3F06E1E8AC9Q28537862-8D0B5BD5-7D19-4B2A-8759-875BF58A82D2Q30571118-600AFC32-A237-4AC1-917A-E83FC72D8250Q30728815-AD7D2A79-20FA-4D6E-B784-9B5925E27D2AQ33437736-6DC825AA-B762-4A91-84C5-DCC77FED7187Q33690357-25BB6B32-7B3B-4DCE-BA80-B95D35925C63Q33776950-0C7AAA92-23DD-4DBC-8C6B-39DDC770A642Q33786577-66F010E0-5750-426B-A21C-27A5B5AB4A26Q33994570-F8165AEC-6989-4D00-BD94-31B71A7E5A12Q34065757-3294CCD8-4656-40A1-AD17-5C8DEE91B6DAQ34216710-EE567356-D8CC-4C00-BE84-C376546D5C4AQ34276618-FE13E0D3-9857-4E9B-BF1B-F9863859D7DEQ34340098-CEE04DC0-26D4-4B1B-AD7C-2DE1452D43FDQ34570995-EDFE73E8-6FD2-4568-A2D1-476F7093C62FQ34612244-A24995CC-B956-4382-96AE-D5E00F868BB5Q34680467-166D469A-49FA-4F99-AC5E-11731F2B42A2Q34777362-DC9DC663-49D3-49E1-9E15-75C40E079537Q35080119-8F614718-8C96-42B8-B114-79160A98ED38Q35088420-718DBB2C-C98F-4E07-A0AF-C3826866A540Q35135638-034D7FE6-8F85-4633-AF5B-054908C7E869Q35158967-A6F32EBA-A589-4123-A0D4-E7CB7D293C5EQ35297067-6196D786-D10A-4174-8DCA-F8A0FE94041CQ35617587-973845DA-1106-4D98-94B7-2B529864CA7FQ35634476-D81B733A-3790-4D16-A038-33DE0B0FAEC5Q35827517-88258791-00BD-485B-AF27-1F68D852849DQ35827696-852D9F04-E839-4069-A94A-F8BE63CDD1A6Q35827882-8B715A9E-0BAF-40F5-B7A3-49197D3A0C68Q35964012-3FCF5701-BA46-413F-9C70-1B4B2E73432DQ36024636-BC515F56-E991-4717-BA97-B88BB9E4A073Q36111214-4D502E2D-3374-4336-B85C-D5B9019CCD43Q36184009-99B8D5AC-EB06-4CF3-829C-99CC8605FAD7Q36192738-78099609-1FE5-4324-B5A7-0C3129FB3267Q36426816-7E881B5D-8A69-4403-8D15-2BFBD69ABD46Q36475040-947E7C50-3154-4395-8C5D-EC76E6300CC0
P2860
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@ast
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@en
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@nl
type
label
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@ast
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@en
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@nl
prefLabel
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@ast
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@en
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@nl
P2093
P50
P3181
P1476
High plasma pravastatin concen ...... olypeptide-C (OATP-C, SLCO1B1)
@en
P2093
Carl Kyrklund
Kari T Kivistö
Martin F Fromm
Matthias Schwab
Michel Eichelbaum
Reinhold Kerb
Thomas Lang
P304
P3181
P356
10.1097/01.FPC.0000114750.08559.32
P407
P577
2004-07-01T00:00:00Z